These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33022750)

  • 21. The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long-term outcome in locally advanced rectal cancer.
    McMahon RK; O'Cathail SM; Nair H; Steele CW; Platt JJ; Digby M; McDonald AC; Horgan PG; Roxburgh CSD
    Colorectal Dis; 2023 Sep; 25(9):1783-1794. PubMed ID: 37485654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No benefit after neoadjuvant chemoradiation in stage IV rectal cancer: A propensity score-matched analysis on a real-world population.
    Milito P; Sorrentino L; Pietrantonio F; Di Russo A; Citterio D; Mazzaferro V; Cosimelli M
    Dig Liver Dis; 2021 Aug; 53(8):1041-1047. PubMed ID: 33487580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of adjuvant chemotherapy after neoadjuvant radio- or radiochemotherapy for patients with locally advanced rectal cancer.
    Lichthardt S; Zenorini L; Wagner J; Baur J; Kerscher A; Matthes N; Kastner C; Pelz J; Kunzmann V; Germer CT; Wiegering A
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2363-2373. PubMed ID: 28756493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of Restaging Pelvis Magnetic Resonance Imaging After Neoadjuvant Concurrent Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
    Fahmawi Y; Smith C; Grimm L; Khullar S; Rider P; Hunter J; Iliff G; Mneimneh W; Roveda K; Wang B; Prodduturvar P; Alkharabsheh O; McCormick B; Mizrahi M; Khushman M
    Clin Colorectal Cancer; 2020 Dec; 19(4):e281-e287. PubMed ID: 32694005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
    Jiang D; Wang X; Wang Y; Philips D; Meng W; Xiong M; Zhao J; Sun L; He D; Li K
    Virchows Arch; 2019 Jul; 475(1):39-47. PubMed ID: 31056731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.
    Hammarström K; Nunes L; Mathot L; Mezheyeuski A; Lundin E; Korsavidou Hult N; Imam I; Osterlund E; Sjöblom T; Glimelius B
    Int J Cancer; 2024 Jul; 155(1):40-53. PubMed ID: 38376070
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer: A Comparison of Short- and Long-term Oncologic Outcomes.
    Goffredo P; Khan A; Mott SL; Jensen CC; Madoff RD; Gaertner WB; You YN; Hassan I
    Ann Surg; 2022 Dec; 276(6):e819-e824. PubMed ID: 34353995
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score.
    Roselló S; Frasson M; García-Granero E; Roda D; Jordá E; Navarro S; Campos S; Esclápez P; García-Botello S; Flor B; Espí A; Masciocchi C; Valentini V; Cervantes A
    Clin Colorectal Cancer; 2018 Jun; 17(2):104-112.e2. PubMed ID: 29162332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
    Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
    Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.
    Peng J; Lv J; Peng J
    Int J Colorectal Dis; 2021 Aug; 36(8):1781-1790. PubMed ID: 33760952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved survival with adjuvant chemotherapy in locally advanced rectal cancer patients treated with preoperative chemoradiation regardless of pathologic response.
    Gahagan JV; Whealon MD; Phelan MJ; Mills S; Jafari MD; Carmichael JC; Stamos MJ; Zell JA; Pigazzi A
    Surg Oncol; 2020 Mar; 32():35-40. PubMed ID: 31726418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
    Yoon G; Lee H; Kim JH; Hur K; Seo AN
    Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in body composition during neoadjuvant therapy can affect prognosis in rectal cancer patients: An exploratory study.
    De Nardi P; Salandini M; Chiari D; Pecorelli N; Cristel G; Damascelli A; Ronzoni M; Massimino L; De Cobelli F; Braga M
    Curr Probl Cancer; 2020 Apr; 44(2):100510. PubMed ID: 31703987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
    Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
    Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
    Lin S; Lai H; Qin Y; Chen J; Lin Y
    Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
    Krajnović M; Marković B; Knežević-Ušaj S; Nikolić I; Stanojević M; Nikolić V; Šiljić M; Jovanović Ćupić S; Dimitrijević B
    Pathol Res Pract; 2016 Jul; 212(7):598-603. PubMed ID: 27184911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
    Jiang DM; Raissouni S; Mercer J; Kumar A; Goodwin R; Heng DY; Tang PA; Doll C; MacLean A; Powell E; Price-Hiller J; Monzon J; Cheung WY; Vickers MM
    Ann Oncol; 2015 Oct; 26(10):2102-6. PubMed ID: 26232491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 39. Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.
    Zhang Q; Liang J; Chen J; Mei S; Wang Z
    Asian Pac J Cancer Prev; 2021 May; 22(5):1607-1611. PubMed ID: 34048192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
    Dudani S; Marginean H; Tang PA; Monzon JG; Raissouni S; Asmis TR; Goodwin RA; Gotfrit J; Cheung WY; Vickers MM
    BMC Cancer; 2019 Jul; 19(1):664. PubMed ID: 31277604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.